Investigational drug · Phase 2
SFG-02
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Participants With Underactive Bladder (UAB).
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SFG-02"
First trial start
2026
Aug 22, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SFG-02", any sponsor or status.
Conditions studied
As listed on its trial records.
- Participants With Underactive Bladder (UAB)
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "SFG-02" as an intervention, largest first.
Juro Sciences Inc.Industry
NCT07906106 · 70 participants (planned) · Start Aug 22, 2026 · Primary completion Feb 28, 2028
Drug: SFG-02; Placebo · For: Participants With Underactive Bladder (UAB)
Sites: Nagoya, Japan; Ōbu, Japan; Katori-shi, Japan · 16 sites in all
Juro Sciences Inc.Industry
NCT07167914 · 32 participants · Start Sep 9, 2025 · Primary completion Apr 27, 2026
Drug: SFG-02; Placebo · For: Health Participants
Sites: Tokyo, Japan
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.